Quality of life in ICON7: need for patients' perspectives
Mené sur 1 538 patientes atteintes d'un cancer épithélial de l'ovaire de stade I-IV, cet essai de phase III (ICON7) évalue, du point de vue de la qualité de vie, l'ajout de bevacizumab à une chimiothérapie de première ligne
Despite the publication of several phase 3 trial showing a progression-free-survival benefit when bevacizumab is added to standard chemotherapy regimens, evidence for the drug's use in ovarian cancer continues to evolve. In The Lancet Oncology, Dan Stark and colleagues4 expand on the quality-of-life findings of the International Collaboration on Ovarian Neoplasms (ICON7) trial, a large, multicentre, phase 3 trial examining the addition of bevacizumab (during chemotherapy and as maintenance for 12 additional cycles) to platinum-based chemotherapy for the primary treatment of ovarian cancer...
The Lancet Oncology , commentaire, 2012